Crossix announced today the launch of DIFA Data Stream, the latest enhancement to its industry leading marketing analytics platform, Crossix DIFA™. More than 150 health brands use DIFA to understand and improve the impact of their marketing investments on patient and healthcare provider (HCP) behavior. With DIFA Data Stream, all underlying DIFA data will be available as a direct data feed to marketers’ data warehouses or data lake environments to support further in-house analytics and reporting.
As more life sciences customers bring commercial data in-house, it is critical to establish appropriate privacy-safe methodologies for in-house analytics. DIFA Data Stream provides opportunities for deep-dives into the analytics, while virtually eliminating privacy and re-identification risks associated with using de-identified patient-level information. The micro-cohorts protect the privacy of individuals, while aligning with both HIPAA guidelines and the Network Advertising Initiative (NAI) Code of Conduct for measurement of digital health campaigns.
DIFA Data Stream will be available for all DIFA products, providing open and direct access to life sciences companies at no additional cost. Clients will often have access to millions of data points that can be used for more granular marketing analyses, based on campaign size. Future versions planned for later this year will include additional data, beyond what is currently available in DIFA, delivering granular, micro-cohort metrics.
“Advanced analytics has become the industry standard to drive marketing ROI. The next logical step is for customers to be able to integrate their marketing performance data with the rest of their commercial data,” said Dan Stein, SVP of Product Strategy at Crossix. “With DIFA Data Stream, customers can tap into the full power of the data, without compromising privacy or quality.”
About the Crossix DIFA™ Platform
Crossix DIFA is the market leading SaaS platform used by healthcare brands and agencies for measuring and optimizing healthcare marketing. The full DIFA suite of products includes:
- DIFA™ Display, Video & Mobile: Connects digital DTC display, video and mobile campaigns to patient behavior for an always-on view of campaign performance
- DIFA TV™: Measures and optimizes linear TV to tie campaign performance to health business objectives
- DIFA Site™: Surpasses traditional web analytics to understand visitors’ health behavior and optimizes brand sites and traffic-drivers, including paid search
- DIFA HCP™: Validates that digital campaigns reach target HCPs and connects exposure to HCP prescribing behavior
- DIFA HCP Site™: Optimizes HCP customer experience on websites by validating the type of customer engaging, such as target/non-target, by decile and by recent field activity, and then links engagement to HCP prescribing behavior
Learn more about the future development of the Crossix DIFA Platform at Veeva Commercial & Medical Summit on June 9-10, 2020. Register for the online event and stay up-to-date on program details at Crossix.com/summit.
About Crossix Solutions, A Veeva Company
A pioneer in patient data, privacy, and analytics, Crossix leverages the industry’s most advanced technology to connect comprehensive health and non-health data, covering more than 300 million lives – all in a privacy-safe way. It delivers data and insights to over 200 brands from top 20 pharma companies as well as leading health systems, pharmacies, and wellness brands. For more information, visit crossix.com.
This release contains forward-looking statements, including expectations regarding the market demand for and acceptance of the data, analytics, software solutions, and services offered by Crossix, a Veeva company, and the results and benefits from use of such offerings. Any forward-looking statements contained in this press release are based upon Crossix’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Crossix’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Crossix and Veeva disclaim any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including whether demand for Crossix’s offerings will grow as anticipated; the competitive environment in the industry; and general market and business conditions (including the on-going impact of COVID-19). Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Veeva’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.